Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines
作者： Helena Faust , Lars Toft , Peter Sehr , Martin Müller , Jesper Bonde
DOI: 10.1016/J.VACCINE.2016.02.019
关键词:
摘要: Ninety-one HIV-infected individuals (61 men and 30 women) were randomized to vaccination either with quadrivalent (Gardasil™) or bivalent (Cervarix™) HPV vaccine. Neutralizing specific HPV-binding serum antibodies measured at baseline 12 months after the first vaccine dose. Presence of neutralizing binding had good agreement (average Kappa for types 6, 11, 16, 18, 31, 33 45 was 0.65). At baseline, 88% subjects against least one genital HPV. Following Cervarix™, all became seropositive HPV16 18. After Gardasil™ vaccination, 96% seroconverted 73% HPV18. Levels HPV16-specific 10IU in 85% study vaccination. Antibodies non-vaccine appeared >50% vaccinated females 35 73 Cervarix™-vaccinated 33, 35, 45, 56 58. Cross-reactivity non-genital also detected. In conclusion, responded induction both types.
sci-hub.se 参考文章(21)
John T. Schiller, Xavier Castellsagué, Suzanne M. Garland, A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines Vaccine. ,vol. 30, ,(2012) , 10.1016/J.VACCINE.2012.04.108
Diana V Pastrana, Christopher B Buck, Yuk-Ying S Pang, Cynthia D Thompson, Philip E Castle, Peter C FitzGerald, Susanne Krüger Kjaer, Douglas R Lowy, John T Schiller, Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18 Virology. ,vol. 321, pp. 205- 216 ,(2004) , 10.1016/J.VIROL.2003.12.027
Douglas M Herrin, Emily E Coates, Pamela J Costner, Troy J Kemp, Martha C Nason, Kapil K Saharia, Yuanji Pan, Uzma N Sarwar, Lasonji Holman, Galina Yamshchikov, Richard A Koup, Yuk Ying S Pang, Robert A Seder, John T Schiller, Barney S Graham, Ligia A Pinto, Julie E Ledgerwood, Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus Human Vaccines & Immunotherapeutics. ,vol. 10, pp. 3446- 3454 ,(2014) , 10.4161/HV.34408
Rolando Herrero, Paula González, Lauri E Markowitz, Present status of human papillomavirus vaccine development and implementation Lancet Oncology. ,vol. 16, ,(2015) , 10.1016/S1470-2045(14)70481-4
Jesper Bonde, Matejka Rebolj, Ditte Møller Ejegod, Sarah Preisler, Elsebeth Lynge, Carsten Rygaard, None, HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system BMC Infectious Diseases. ,vol. 14, pp. 413- 413 ,(2014) , 10.1186/1471-2334-14-413
Helena Faust, Mateja M. Jelen, Mario Poljak, Irena Klavs, Veronika Učakar, Joakim Dillner, Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types. Journal of Clinical Virology. ,vol. 56, pp. 336- 341 ,(2013) , 10.1016/J.JCV.2012.12.004
Matti Lehtinen, Joakim Dillner, Clinical trials of human papillomavirus vaccines and beyond Nature Reviews Clinical Oncology. ,vol. 10, pp. 400- 410 ,(2013) , 10.1038/NRCLINONC.2013.84
Peter Sehr, Ivonne Rubio, Hanna Seitz, Kerstin Putzker, Lis Ribeiro-Müller, Michael Pawlita, Martin Müller, High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses PLoS ONE. ,vol. 8, pp. e75677- ,(2013) , 10.1371/JOURNAL.PONE.0075677
Christine Roberts, Tina Green, Erica Hess, Katie Matys, Martha J Brown, Richard M Haupt, Alain Luxembourg, Scott Vuocolo, Alfred Saah, Joseph Antonello, Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types. Human Vaccines & Immunotherapeutics. ,vol. 10, pp. 2168- 2174 ,(2014) , 10.4161/HV.29205
Carina Eklund, Elizabeth R. Unger, Denise Nardelli-Haefliger, Tiequn Zhou, Joakim Dillner, International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine. ,vol. 30, pp. 294- 299 ,(2012) , 10.1016/J.VACCINE.2011.10.096